The fundamental purpose of SonoVue is to enhance diagnostic certainty when standard ultrasound is inconclusive, which supports patient management for the underlying conditions causing the patient's distress.

SonoVue is commonly used in clinical settings involving Diagnostic Ambiguity across several key areas. These include supporting the clear delineation of the cardiac chambers in patients with suspected cardiovascular disease, assisting in the accurate assessment of blood flow in major vessels (macrovasculature), and enabling more specific characterization of ambiguous focal lesions in the liver or breast. The agent is also relevant in pediatric patients for the non-invasive identification of vesicoureteral reflux (VUR). This assists with maintaining functional stability by reducing the burden of diagnostic uncertainty.

“The primary goal is supporting the transition from an inconclusive diagnostic challenge to a clearer visual assessment, which assists informed next steps for the patient.”

This supports general well-being by assisting clinical decisions, which may help ease the overall symptom load.

---

Quick Fact: Clarity for Cardiovascular Assessment The agent is commonly used to support assessment in situations where the endocardial border of the left ventricle is not clearly visible on unenhanced ultrasound, which is relevant in conditions associated with cardiovascular assessment.

Regulatory References

1. European Medicines Agency

Who Can and Cannot Use Соновью (SonoVue)?

Eligibility for SonoVue, a prescription-only diagnostic agent, is strictly defined by regulatory authorities based on age, the specific diagnostic procedure, and pre-existing medical conditions.

---

Approved Populations and Uses

SonoVue is approved for use in Adult Patients for all intravenous indications (e.g., echocardiography and vascular imaging). Paediatric Patients (newborn to 18 years) are eligible only for the non-intravenous, intravesical route of administration used to detect vesicoureteral reflux (VUR). Intravenous use in children and adolescents is not established and is therefore not permitted.

Absolute Contraindications

SonoVue must not be used if a patient has a known hypersensitivity to the active substance (Sulfur Hexafluoride) or any excipients. Intravenous use is also contraindicated in patients with specific severe conditions, including right-to-left cardiac shunts, severe pulmonary hypertension (Pulmonary Artery Pressure > 90 mmHg), uncontrolled systemic hypertension, and Adult Respiratory Distress Syndrome (ARDS).

---

Restrictions and Special Caution

Use requires extreme caution and close monitoring in patients with recent acute coronary syndrome or unstable ischaemic cardiac disease. Furthermore, the agent is generally not recommended during pregnancy or lactation due to a lack of established safety and efficacy data.

SonoVue Interactions with other medicines and products

Official regulatory documentation notes that no dedicated pharmacokinetic interaction studies have been performed to assess the potential for SonoVue (Sulfur Hexafluoride) to interact with other medicinal products. The documented interaction profile is restricted to specific pharmacodynamic combination restrictions and general safety cautions.

---

Interaction Restrictions and Cautions

Classification	Interacting Agents / Conditions
Conditional Contraindication	Co-administration with Dobutamine is strictly prohibited in patients who have conditions suggesting cardiovascular instability where the use of dobutamine is already contraindicated.
Use with Caution	Medicines known to prolong the QT interval (due to potential additive pharmacodynamic effect) and treatment with Epinephrine in patients on Beta Blockers (due to a cautioned response during anaphylaxis management).

---

Regulatory Basis

The product's core active component, sulfur hexafluoride gas, is primarily eliminated via exhalation, which minimizes the likelihood of systemic metabolic interactions. As such, regulatory guidelines contain no mandatory timing rules or dose adjustments required for co-administration based on altered clearance or exposure of other medicines. The restrictions focus instead on specific clinical contexts and patient status.

How Соновью Works: Mechanism of Action

---

Acoustic Contrast Amplification and Non-Linear Echo Generation

The mechanism of action for Соновью is purely physical and acoustic, relying on the microbubble's unique structure to interact with ultrasound waves. The Sulfur Hexafluoride ( SF6) gas core provides a drastic acoustic impedance mismatch against the blood, causing the microbubble to undergo controlled, non-linear oscillation (resonance) when struck by the ultrasound beam. This resonance generates powerful harmonic echoes, which drastically increase the echogenicity (brightness) of the blood pool, creating intense acoustic contrast, which results in a dramatic increase in signal-to-noise ratio.

---

Vascular Tracing and Systemic Circulation Confinement

The microbubble's small, stable size enables transpulmonary passage, facilitating its circulation through the pulmonary capillaries and entry into the systemic circulation (the entire blood pool). The phospholipid shell prevents the rapid dissolution of the SF6 gas, ensuring the microbubbles remain structurally intact and entirely confined to the vasculature. This sustained presence allows the agent to function as a systemic vascular tracer, revealing flow dynamics in both large vessels and the microvascular perfusion in tissues.

---

Mechanism Constraint via Acoustic Sensitivity

The integrity of this acoustic mechanism is governed by its sensitivity to physical force. The microbubbles are prone to rapid physical destruction (rupture) when exposed to high acoustic energy, specifically high Mechanical Index ( MI) settings on the ultrasound equipment. This constraint requires the use of low-power acoustic settings to maintain the controlled oscillation and sustain the duration of the acoustic signal.

SonoVue is a prescription-only diagnostic agent administered either intravenously or intravesically, depending on the patient's age and the specific diagnostic context. The intravenous (IV) route is utilized for adults undergoing echocardiography or vascular Doppler assessments. For B-mode echocardiography, the standardized adult dose is 2 mL administered as a bolus injection. When used for vascular Doppler imaging, the dose prescribed is 2.4 mL. Administration of the agent is procedural and restricted to the time of the single diagnostic examination; a single repeat injection of the original dose may be permitted during the procedure if deemed necessary.

The agent is supplied as a powder and must be prepared prior to use. Reconstitution requires mixing the vial with 5 mL of 0.9% sodium chloride solution, followed by vigorous shaking for 20 seconds to form the functional microbubble dispersion. A critical procedural step for intravenous administration is the requirement for an immediate 5 mL flush of 0.9% sodium chloride following every injection. The reconstituted agent must be administered without delay after being drawn into the syringe.

Dosing is generally consistent for older adults, who receive the standard adult IV dose. However, intravenous use in pediatric patients has not been established. For children undergoing specialized urinary tract ultrasonography (VUR assessment), the recommended dose is 1 mL administered via the intravesical route. Use of the agent is mandated to occur under the supervision of physicians experienced in diagnostic ultrasound imaging.

Research Evidence / Overview of Studies for Соновью

This section provides an overview of the evidence that informed the regulatory approval of Соновью, focusing only on the structure of the research (what was studied) and the patterns described in the findings. This information reflects group patterns from specific studies and is not intended to provide individual medical or diagnostic predictions.

---

Evidence for Clarity in Cardiovascular Ultrasound (Echocardiography)

The research supporting the use of Соновью in the heart relies on short-term, multi-center Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving adults whose standard, unenhanced ultrasound scans were inconclusive. Studies monitored technical outcomes related to image quality, specifically using scores for Left Ventricular Endocardial Border Delineation (LVEBD) and overall heart chamber opacification.

Research describes the patterns observed in the studies related to measured image delineation and opacification immediately following the agent's administration. Studies reported measurements where the agent was observed in relation to the visibility of the heart’s internal structures. This is considered a technical, short-term outcome, and research provides context but not individual predictions.

Long-term effects are not fully established, and there is limited information for long-term outcomes for patients beyond the acute diagnostic procedure itself.

---

Evidence for Blood Flow Assessment (Macrovasculature)

Research explored the agent’s use in Doppler tests to assess blood flow dynamics in large blood vessels. Comparative studies were evaluated in adults being assessed for various vascular conditions. Findings indicate patterns related to observations of signal enhancement and technical visibility in specific vessels, such as the portal and carotid arteries.

However, the evidence quality varies across studies, as regulatory summaries reported that the changes in enhancement were not consistently observed across all vascular beds studied, noting that data for vessels like the renal arteries were mixed or insufficient.

---

Evidence for Characterizing Ambiguous Lesions (Microvasculature)

Research supporting this use involves systematic reviews and Phase III Intrapatient Comparative Studies examining adults with lesions that were indeterminate following a standard ultrasound scan. The research was applied in studies examining the lesion’s internal blood flow pattern, which is a factor used in diagnostic classification.

Studies reported that the procedure for assessing lesion characteristics occurred over the different phases of contrast uptake. The agent was studied for use only when the unenhanced ultrasound is inconclusive; evidence does not exist to support using the agent for general screening purposes.

---

Evidence for Use in Pediatric Diagnostics

The agent was studied for use in the pediatric population (birth to 18 years) for the assessment of vesicoureteral reflux (VUR). Studies reported the physical detection of the agent in the ureters or kidneys in a number of children where VUR was confirmed.

Regulatory documents noted a key uncertainty: the evidence was insufficient to definitively exclude VUR based solely on a negative result using the contrast-enhanced method. Follow-up durations were limited to the acute diagnostic setting.

Common questions about Соновью (FAQ)

---

Q: How quickly can a person expect Соновью to start working?

Studies and official information indicate that the full enhancement effect is described as being seen rapidly upon administration during the diagnostic procedure itself. Regulatory documents describe that the active component, sulfur hexafluoride, reaches its maximum concentration in the blood within approximately one to two minutes after an intravenous injection.

---

Q: What is the typical timeframe before the effects of Соновью wear off?

The duration of the acoustic contrast signal is reported to vary depending on the specific type of ultrasound assessment being performed. Official information indicates that the active gas component has a short terminal half-life of approximately 10 minutes in the body, as it is primarily eliminated by exhalation.

---

Q: Are there any known interactions between Соновью and common pain relievers?

Official product information notes that no specific pharmacokinetic interaction studies have been conducted with other medicines. Clinical studies involving patients receiving various categories of the most common concomitant medications did not specifically highlight any unique interaction patterns.

---

Q: Can Соновью be taken with certain vitamins or mineral supplements?

Regulatory documentation states that no specific interaction studies have been performed with other medicinal products, including vitamins or supplements. Since the active gas component is eliminated primarily via exhalation, the risk of systemic metabolic interaction is described as minimized.

---

Q: How long does a person need to take Соновью to see its full effect?

Соновью is a diagnostic agent and is not taken over a period of time like a chronic medication. Its use is restricted to the time of a single diagnostic examination, and the image enhancement effect is reported to occur rapidly during the procedure itself.

---

Q: Is it necessary to have routine blood work done while on Соновью?

Regulatory guidance notes that close monitoring, such as ECG monitoring, should be performed in high-risk patients as clinically indicated due to the risk of serious cardiopulmonary reactions. Precautions regarding routine laboratory monitoring are not generally noted in the official usage precautions.

---

Q: Is it true that Соновью is only for short-term use?

Yes, Соновью is classified as a diagnostic agent and is not intended for chronic use. Its application is restricted to enhancing a single diagnostic examination and is not approved for long-term or repeated treatment administration.

---

Q: Can Соновью be used by adults over the age of 65?

Yes. Regulatory documents indicate that dosing for older adults is generally consistent with the standard adult intravenous dose. The standard adult dose is used for patients in this age group.

---

Q: Will I need to change my diet while using Соновью?

The official product information does not specify any mandatory timing rules or dose adjustments related to food or diet. There are no restrictions noted on diet related to the use of the agent.

---

Q: Is Соновью a once-a-day medicine?

No, Соновью is not a medicine taken daily. It is a diagnostic agent restricted to administration during a single diagnostic procedure and is not used for ongoing treatment.

---

Q: Can the effectiveness of Соновью decrease if it's used for a long time?

Regulatory documents state that studies supporting approval were short-term. The agent is not approved for long-term use, and therefore, information regarding the long-term effectiveness or potential decrease in effectiveness following repeated use is not established in the product label.

---

Q: Are there any known interaction issues with birth control pills and Соновью?

Official documentation notes that no specific pharmacokinetic interaction studies have been conducted, including those with birth control pills. The product's mechanism of elimination via exhalation minimizes systemic metabolic interaction risks, and no specific interaction with birth control is noted.

---

Q: Are there any specific organs that Соновью is known to affect?

The agent is designed to function within the blood pool and is used to enhance imaging in the heart, major and minor blood vessels, and the urinary tract (in children). Its mechanism is confined entirely to the bloodstream/vessels or the bladder.

---

Q: Are there different forms of the drug (e.g., tablet, liquid, injection)?

Соновью is supplied as a powder and solvent for dispersion for injection. It is not available in oral forms, such as tablets or capsules.

---

Q: Why are there warnings about suddenly stopping the use of Соновью?

The product label does not contain warnings about suddenly stopping the use of Соновью. This is because the agent is a diagnostic product administered only during a single procedure and is not a medication used for chronic therapy.

---

Q: Is Соновью the first line of treatment for its approved condition?

No. Official documents state that the agent should only be used in patients where study without contrast enhancement is inconclusive, indicating it is a secondary or clarifying diagnostic step, not a first-line procedure.

---

Q: What is the general success rate described in clinical trial summaries?

Clinical trial summaries focus on technical measures of success, such as improvements in image quality and the visibility of internal structures. They report on enhanced visualization scores, such as Left Ventricular Endocardial Border Delineation, rather than reporting a single, generalized 'success rate' percentage.

How to Store and Dispose of Соновью?

The official regulatory labeling specifies mandatory conditions for storing and handling the SonoVue powder and solvent kit, as well as the dispersion.

Storage Requirements

Condition	Requirement (Unreconstituted Kit)
Temperature	Store at room temperature, between 15°C and 30°C (59°F and 86°F).
Protection	Keep in a cool, dry place, and in well-sealed receptacles.
Child-Safety	Must be kept out of the sight and reach of children.

Stability and Disposal

Once the powder is reconstituted, the microbubble dispersion is only stable and usable for a maximum of six hours. The product must be agitated immediately prior to use to re-suspend the microbubbles. Disposal of any unused or expired product, including waste material, must be conducted in accordance with local regulatory requirements.